Sarepta Therapeutics, Inc. SRPT Contingent Consideration Liability (Non-Current)
Contingent Consideration Liability (Non-Current) at other companies
Other financials
Where this comes from
Reported directly by Sarepta Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent.
The official record: Sarepta Therapeutics, Inc.’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sarepta Therapeutics, Inc.'s contingent consideration liability (non-current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sarepta Therapeutics, Inc.'s contingent consideration liability (non-current)?
- Sarepta Therapeutics, Inc. (SRPT) reported contingent consideration liability (non-current) of $0 in Q4 2025.
- How has Sarepta Therapeutics, Inc.'s contingent consideration liability (non-current) changed year-over-year?
- Sarepta Therapeutics, Inc.'s contingent consideration liability (non-current) decreased by 100.0% year-over-year, from $47.4M to $0.
- What is the long-term trend for Sarepta Therapeutics, Inc.'s contingent consideration liability (non-current)?
- Over 5 years (2020 to 2025), Sarepta Therapeutics, Inc.'s contingent consideration liability (non-current) has grown at a -100.0% compound annual growth rate (CAGR), from $50.8M to $0.
- What does contingent consideration liability (non-current) mean?
- This liability represents the estimated fair value of future payments owed to sellers following a business acquisition, contingent upon the achievement of specific performance milestones or regulatory outcomes. It serves as a marker for the company's inorganic growth strategy and the long-term financial obligations tied to past M&A activity. Investors use this to understand potential future cash outflows and the risk profile associated with acquired assets.